|
1
|
Baselga J, Norton L, Albanell J, Kim YM
and Mendelsohn J: Recombinant humanized anti-HER2 antibody
(Herceptin) enhances the antitumor activity of paclitaxel and
doxorubicin against HER2/neu overexpressing human breast cancer
xenografts. Cancer Res. 58:2825–2831. 1998.
|
|
2
|
Cleator S, Heller W and Coombes RC:
Triple-negative breast cancer: therapeutic options. Lancet Oncol.
8:235–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rakha EA and Ellis IO:
Triple-negative/basal-like breast cancer: review. Pathology.
41:40–47. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gluz O, Liedtke C, Gottschalk N, Pusztai
L, Nitz U and Harbeck N: Triple-negative breast cancer - current
status and future directions. Ann Oncol. 20:1913–1927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carey L, Winer E, Viale G, Cameron D and
Gianni L: Triple-negative breast cancer: disease entity or title of
convenience? Nat Rev Clin Oncol. 7:683–692. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pérez de Castro I, de Cárcer G, Montoya G
and Malumbres M: Emerging cancer therapeutic opportunities by
inhibiting mitotic kinases. Curr Opin Pharmacol. 8:375–383.
2008.PubMed/NCBI
|
|
7
|
Chi YH and Jeang KT: Aneuploidy and
cancer. J Cell Biochem. 102:531–538. 2007. View Article : Google Scholar
|
|
8
|
Kops GJ, Weaver BA and Cleveland DW: On
the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev
Cancer. 5:773–785. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuen KW, Montpetit B and Hieter P: The
kinetochore and cancer: what’s the connection? Curr Opin Cell Biol.
17:576–582. 2005.
|
|
10
|
Fry AM, Mayor T and Nigg EA: Regulating
centrosomes by protein phosphorylation. Curr Top Dev Biol.
49:291–312. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nigg EA: Mitotic kinases as regulators of
cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takai N, Miyazaki T, Fujisawa K, Nasu K,
Hamanaka R and Miyakawa I: Polo-like kinase (PLK) expression in
endometrial carcinoma. Cancer Lett. 169:41–49. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Holtrich U, Wolf G, Bräuninger A, et al:
Induction and down-regulation of PLK, a human serine/threonine
kinase expressed in proliferating cells and tumors. Proc Natl Acad
Sci USA. 91:1736–1740. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li D, Zhu J, Firozi PF, et al:
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human
pancreatic cancer. Clin Cancer Res. 9:991–997. 2003.PubMed/NCBI
|
|
15
|
Bettencourt-Dias M and Glover DM:
Centrosome biogenesis and function: centrosomics brings new
understanding. Nat Rev Mol Cell Biol. 8:451–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krämer A, Neben K and Ho AD: Centrosome
aberrations in hematological malignancies. Cell Biol Int.
29:375–383. 2005.
|
|
17
|
Nigg EA: Centrosome aberrations: cause or
consequence of cancer progression? Nat Rev Cancer. 2:815–825. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schultz SJ, Fry AM, Sütterlin C, Ried T
and Nigg EA: Cell cycle-dependent expression of Nek2, a novel human
protein kinase related to the NIMA mitotic regulator of
Aspergillus nidulans. Cell Growth Differ. 5:625–635.
1994.PubMed/NCBI
|
|
19
|
Fry AM, Schultz SJ, Bartek J and Nigg EA:
Substrate specificity and cell cycle regulation of the Nek2 protein
kinase, a potential human homolog of the mitotic regulator NIMA of
Aspergillus nidulans. J Biol Chem. 270:12899–12905. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fry AM, Meraldi P and Nigg EA: A
centrosomal function for the human Nek2 protein kinase, a member of
the NIMA family of cell cycle regulators. EMBO J. 17:470–481. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Faragher AJ and Fry AM: Nek2A kinase
stimulates centrosome disjunction and is required for formation of
bipolar mitotic spindles. Mol Biol Cell. 14:2876–2889. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayward DG, Clarke RB, Faragher AJ, Pillai
MR, Hagan IM and Fry AM: The centrosomal kinase Nek2 displays
elevated levels of protein expression in human breast cancer.
Cancer Res. 64:7370–7376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsunoda N, Kokuryo T, Oda K, et al: Nek2
as a novel molecular target for the treatment of breast carcinoma.
Cancer Sci. 100:111–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kokuryo T, Senga T, Yokoyama Y, Nagino M,
Nimura Y and Hamaguchi M: Nek2 as an effective target for
inhibition of tumorigenic growth and peritoneal dissemination of
cholangio-carcinoma. Cancer Res. 67:9637–9642. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Crown J and Pegram M: Platinum-taxane
combinations in metastatic breast cancer: an evolving role in the
era of molecularly targeted therapy. Breast Cancer Res Treat.
79(Suppl 1): S11–S18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei R, Ngo B, Wu G and Lee WH:
Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase
modulates chromosome alignment and signaling of the spindle
assembly checkpoint. Mol Biol Cell. 22:3584–3594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jordan MA and Wilson L: Microtubules as a
target for anti-cancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar
|
|
28
|
Blajeski AL, Kottke TJ and Kaufmann SH: A
multistep model for paclitaxel-induced apoptosis in human breast
cancer cell lines. Exp Cell Res. 270:277–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Isaacs RJ, Davies SL, Sandri MI, Redwood
C, Wells NJ and Hickson ID: Physiological regulation of eukaryotic
topoisomerase II. Biochim Biophys Acta. 1400:121–137. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nitiss JL and Beck WT: Antitopoisomerase
drug action and resistance. Eur J Cancer. 32A:958–966. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Spallarossa P, Altieri P, Aloi C, et al:
Doxorubicin induces senescence or apoptosis in rat neonatal
cardiomyocytes by regulating the expression levels of the telomere
binding factors 1 and 2. Am J Physiol Heart Circ Physiol.
297:H2169–H2181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bertrand JR, Pottier M, Vekris A, Opolon
P, Maksimenko A and Malvy C: Comparison of antisense
oligonucleotides and siRNAs in cell culture and in vivo. Biochem
Biophys Res Commun. 296:1000–1004. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Spänkuch-Schmitt B, Bereiter-Hahn J,
Kaufmann M and Strebhardt K: Effect of RNA silencing of polo-like
kinase-1 (PLK1) on apoptosis and spindle formation in human cancer
cells. J Natl Cancer Inst. 94:1863–1877. 2002.PubMed/NCBI
|
|
34
|
Tsui P, Rubenstein M and Guinan P: siRNA
is not more effective than a first generation antisense
oligonucleotide when directed against EGFR in the treatment of PC-3
prostate cancer. In Vivo. 19:653–656. 2005.PubMed/NCBI
|
|
35
|
Lou Y, Yao J, Zereshki A, et al: NEK2A
interacts with MAD1 and possibly functions as a novel integrator of
the spindle checkpoint signaling. J Biol Chem. 279:20049–20057.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fletcher L, Cerniglia GJ, Yen TJ and
Muschel RJ: Live cell imaging reveals distinct roles in cell cycle
regulation for Nek2A and Nek2B. Biochim Biophys Acta. 1744:89–92.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Prime G and Markie D: The telomere repeat
binding protein Trf1 interacts with the spindle checkpoint protein
Mad1 and Nek2 mitotic kinase. Cell Cycle. 4:121–124. 2005.
View Article : Google Scholar : PubMed/NCBI
|
